[Evaluation of the cumulative effect of meglumine antimoniate on the progeny of swiss mice: biologic assay].
OBJECTIVE
Evaluate the effect of Meglumine Antimoniate on maternal-fetal transference in F1 generations (offspring of dams exposed to the drug), and embryotoxicity in F2 generations.


METHODS
Female Swiss mice were treated with daily s.c. injection of Meglumine Antimoniate (100mgSb v/kg bw/day) from day 7 until day 12 of pregnancy. The control group received only the vehicle (distilled water). After birth of offspring (F1 generation), 59 females were examined daily for determination of the estral cycle. When the cycle estrus was determined, males were mated with 18 females of the same lineage. On day 18 of pregnancy, females were euthanasied in a chamber of CO2 and after incision of the abdomen, the uterus was exposed. Then, resorptions as well as living and dead fetuses were evaluated, also the number of embryo/fetal implantation sites. Fetuses and their placenta were weighted to calculate the placental index. Three placentas of each litter were separated for microscopic analysis.


RESULTS
Administration of the Meglumine Antimoniate did not interfere in the estral cycle of the treated group, since it did not alter the precoital interval and fertility index. Placenta alterations were not observed in the F2 generations.


CONCLUSIONS
Meglumine Antimoniate did not interfere in the reproductive performance, after chronic exposition of dams. Data suggest that there is a gradual elimination of Meglumine Antimoniate by the maternal organism without damaging the future offspring.
Santos
Michelle Rodrigues Dos
MR
Universidade Regional Integrada do Alto Uruguai e das Missões, Campus de Erechim, Erechim, RS, Brazil.
Krignl
Clarisse Juliana
CJ
Nava
Alexandra
A
Reik
Camila Michele Sabedot
CM
Silva
Fabiana Ernestina Barcellos da
FE
Roman
Silvane Souza
SS
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000633:toxicity*; D030762:Estrous Cycle / Q000187:drug effects; D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D008431:Maternal-Fetal Exchange; D008536:Meglumine / Q000008:administration & dosage / Q000633:toxicity*; D000077485:Meglumine Antimoniate; D051379:Mice; D023421:Models, Animal; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000633:toxicity*; D010920:Placenta / Q000187:drug effects / Q000473:pathology; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D012098:Reproduction / Q000187:drug effects
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate